All Stories

  1. The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction

    Article • The FASEB Journal, March 2019, Federation of American Societies For Experimental Biology (FASEB)

    Kenneth Tanabe, Lijuan Jiang, Gunisha Arora

  2. Hepatocellular carcinoma: early-stage management challenges

    Article • Journal of Hepatocellular Carcinoma, June 2017, Dove Medical Press

    Kenneth Tanabe

  3. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma

    Article • Hepatology, February 2014, Wolters Kluwer Health

    Kenneth Tanabe

  4. Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review

    Article • British Journal of Dermatology, January 2014, Oxford University Press (OUP)

    Kenneth Tanabe

  5. A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients

    Article • OncoTargets and Therapy, December 2013, Taylor & Francis

    Kenneth Tanabe

  6. Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis

    Article • JAMA, January 2008, American Medical Association (AMA)

    Kenneth Tanabe